Daniel Kowalczyk

Sandoz

Sandoz is a global leader in generic pharmaceuticals and biosimilars. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people's lives. We contribute to society's ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our global portfolio comprises approximately 1,000 molecules, covering all major therapeutic areas, which accounted for 2019 sales of USD 9.7 billion. Our products reach more than 500 million patients. Sandoz is also on Twitter. Follow us on @Sandoz_global and Facebook: https://www.facebook.com/sandozglobal/ See the Sandoz community guidelines: https://www.sandoz.com/sites/www.sandoz.com/files/sandoz-social-media-community-guidelines.pdf